CELESTIMO trial shows mosunetuzumab plus lenalidomide boosts PFS in relapsed follicular lymphoma, supporting earlier-line outpatient, chemo-free care.
|Videos|April 16, 2020
Progress in the Treatment of Follicular Lymphoma
Follicular Lymphoma
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Luciano Costa, MD, Discusses the Changing Treatment Paradigm in Myeloma
3
Dr Matous on Moving T-Cell Redirection Into Frontline Myeloma Care
4
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
5